Group structure
11 companies in 5 countries
Loading your page…
Loading your page…
11 companies in 5 countries
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
24 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| BENZEDRINE10mg | 5mg · Tablet | Amfetamine | United States | Not marketed | 1976 |
| DIMETHICONE PROTECTANT5.0 % / w/w · Cream | Dimethicone | Canada | Marketed | 2008 |
| HEPARIN LOCK FLUSH10 units/ml | 100 units/ml | 500 units/ml · Injectable | Heparin | United States | Not marketed | 1943 |
| HYDRALAZINE HYDROCHLORIDE20mg/ml · Injectable | Hydralazine | United States | Marketed | 1997 |
| IRUXOLUnguento | Chloramphenicol, Collagenasi | Italy | Authorised | |
| IRUXOL MONO POMADA1,2 ui + 0,24 ui · Pomada | Clostridiopeptidasa, Proteasas | Spain | Marketed | 1993 |
| IRUXOL NEO POMADA0,6 UI + 3,5 mg · Pomada | Clostridiopeptidasa, Neomycin | Spain | Marketed | 1973 |
| NORUXOLCrema | Collagenasi | Italy | Authorised | |
| Novuxol, hydrofobe zalfZalf | Clostridiopeptidase a, Collagenase n, Protease | Netherlands | Authorised | 1992 |
| PHENYTOIN SODIUM50mg/ml · Injectable | Phenytoin | United States | Marketed | 1975 |
| PROPRANOLOL HYDROCHLORIDE1MG/ML | 1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Injectable | Propranolol | United States | Marketed | 1967 |
| PROSHIELD PLUS1 % / w/w · Ointment | Dimethicone | Canada | Marketed | 2005 |
| PROTECTIVE OINTMENT98.85 % / w/w · Ointment | Petrolatum | Canada | Marketed | 2024 |
| REGRANEX100ug/g · GEL | Becaplermin | United States | Marketed | 1997 |
| SANTYL250u/gram · Ointment | Collagenase | United States | Marketed | 1965 |
| FLAMAZINE CREAM 1% | Silver sulfadiazine | Saudi Arabia | Authorised | |
| FLAMAZINE CREAM 1% | Silver sulfadiazine | Saudi Arabia | Authorised | |
| BACTIGRAS.5 % / % · Dressing | Chlorhexidine | Canada | Cancelled | 1978 |
| FLAMAZINE1 % · Cream | Silver sulfadiazine | Canada | Cancelled | 1974 |
| FLAMAZINE C2 mg / g + 10 mg / g · Cream | Chlorhexidine, Silver sulfadiazine | Canada | Cancelled | 1987 |
| PROTECTIVE OINTMENT98.79 % / w/w · Ointment | Petrolatum | Canada | Cancelled | 2010 |
| SANTYL250 unit / g · Ointment | Collagenase | Canada | Cancelled | 1994 |
| TAGAMET LIQ 300MG/5ML300 mg / 5 ml · Liquid | Cimetidine | Canada | Cancelled | 1982 |
| TRIPLE CARE CREAM 10%10 % · Cream | Zinc oxide | Canada | Cancelled | 1991 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 10 | 3 | 7 | CompaniesAll medicines |
| United States | 7 | 7 | 0 | CompaniesAll medicines |
| Spain | 2 | 2 | 0 | CompaniesAll medicines |
| Italy | 2 | 2 | 0 | CompaniesAll medicines |
| Saudi Arabia | 2 | 2 | 0 | CompaniesAll medicines |
| Netherlands | 1 | 1 | 0 | CompaniesAll medicines |
Also in the registers of Brazil, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Report an error or request removalCorrections from the company itself are welcome.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Well-known pharmaceutical groups, each with all its companies.